EN-SEMBLE
Not Applicable
- Conditions
- HER2-positive unresectable and/or recurrent breast cancer
- Registration Number
- JPRN-jRCT1030220506
- Lead Sponsor
- Tsurutani Junji
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Recruiting
- Sex
- All
- Target Recruitment
- 1200
Inclusion Criteria
1)Patients who received T-DXd for HER2-positive unresectable and/or recurrent breast cancer between May 25, 2020 and November 30, 2021.
2)Patients enrolled in the Post-marketing Surveillance for interstitial lung disease of ENHERTU in breast cancer patients
3)Patients who started post-treatment after discontinuation of T-DXd
4)Patients who are 18 years of age or older at the start of post-treatment.
5)Patients who have given written informed consent (however, patients who cannot give written informed consent due to death or loss of follow-up will be allowed to opt out).
Exclusion Criteria
1)Patients who are deemed inappropriate by the investigator.
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method